**Supplementary Table S1.** Mechanisms of action and peak serum concentrations (PSC) in mg/L of the 9 antibiotics used in this study

|  |  |  |
| --- | --- | --- |
| Mechanism of action a | Antibiotic | PSC (mg/L) |
| Cell wall synthesis inhibitor | Dicloxacillin | **59**  (Friberg, O.; Jones, I.; Sjöberg, L.; Söderquist, B.; Vikerfors, T. & Källman, J., 2004. Antibiotic concentrations in serum and wound fluid after local gentamicin or intravenous dicloxacillin prophylaxis in cardiac surgery. *Scand J Infect Dis.*, 35(4):251-254) |
| Teicoplanin | **50**  (Mensa, J., 1998. *Guía terapéutica antimicrobiana* 8th ed., Masson) |
| Vancomycin | **40**  (National Committee for Clinical Laboratory Standards, 1997. *Methods for dilution: antimicrobial susceptibility tests for bacteria that grow aerobically - Fifth Edition: Approved Standard M7-A5*, Wayne, PA, USA: NCCLS) |
| Nucleic acids synthesis inhibitor | Ciprofloxacin | **4.5**  (Bayer HealthCare Pharmaceuticals Inc., 2004. CIPRO (R) (ciprofloxacin hydrochloride) Tablets, pp.1–31 ) |
| Rifampicin | **10**  (National Committee for Clinical Laboratory Standards, 1997. *Methods for dilution: antimicrobial susceptibility tests for bacteria that grow aerobically - Fifth Edition: Approved Standard M7-A5*, Wayne, PA, USA: NCCLS) |
| Protein synthesis inhibitor | Erythromycin | **10**  (Bennett, J.E.; Dolin, R. & Blaser, M.J., 2014. Basic principles in the diagnosis and management of infectious diseases. In *Principles and Practice of Infectious Diseases,* pp. 358–376, Philadelphia, PA, Elsevier Saunders) |
| Gentamicin | **10**  (Demczar, D.J.; Nafziger, A.N. & Bertino, J.S., 1997. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing. *Antimicrobial Agents and Chemotherapy*, 41(5), pp.1115–1119) |
| Linezolid | **18**  (Prydal, J.I.; Jenkins, D.R.; Lovering, A. & Watts, A., 2005. The pharmacokinetics of linezolid in the non-inflamed human eye. *The British journal of ophthalmology*, 89(11), pp.1418–9) |
| Tetracycline | **16**  (National Committee for Clinical Laboratory Standards, 1997. *Methods for dilution: antimicrobial susceptibility tests for bacteria that grow aerobically - Fifth Edition: Approved Standard M7-A5*, Wayne, PA, USA: NCCLS) |

a The mechanism of action of the antibiotics was determined by the information sheet provided by the antibiotics manufacturer.